New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 15, 2013
10:21 EDTPFE, GSKViiV Healthcare granted FDA priority review for dolutegravir
ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK) and Pfizer (PFE), announced that the U.S. Food and Drug Administration has granted a priority review designation to dolutegravir submitted for the treatment of HIV infection, in combination with other antiretroviral agents, in adults and adolescents. The FDA has assigned dolutegravir a Prescription Drug User Fee Act target date of August 17, 2013. ViiV Healthcare submitted a Marketing Authorisation Application for dolutegravir to the European Medicines Agency on December 17, 2012.
News For GSK;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
October 2, 2015
08:16 EDTPFEPfizer upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Pfizer to Overweight and raised its price target to $38 from $35. Analyst David Risinger expects revenue growth to turn positive in 2016 after years of declines and said Pfizer has a strong balance sheet to take advantage of weakness in the pharma and biotech sectors. Risinger sees share upside with limited downside risk as fundamentals improve and management takes advantage of its strong financial position.
October 1, 2015
08:04 EDTGSK, PFEPfizer completes acquisition of Nimerix, Mencevax from GSK
Pfizer (PFE) announced that it has completed the acquisition of GlaxoSmithKline's (GSK) quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
07:39 EDTPFEJPMorgan sees opportunities in pharma after pullback
Subscribe for More Information
07:31 EDTPFELeerink to hold a roundtable
Subscribe for More Information
September 30, 2015
12:41 EDTGSKGlaxoSmithKline exercises option for Liquidia Technologies' inhaled therapeutics
Liquidia Technologies announced that GlaxoSmithKline has exercised its option under a Collaboration and Option Agreement signed in 2012 to exclusively license the right to research, develop, and commercialize inhaled therapeutics derived from the company's proprietary PRINT technology. Through this collaboration, Liquidia and GSK will continue to work together with the goal of advancing inhaled therapeutics into clinical studies. According to the agreement signed in June 2012, Liquidia was granted an upfront payment comprised of cash and equity, R&D funding, and potential development milestones and royalties. As a result of the GSK decision to exercise the option, Liquidia will receive an option fee, continued R&D funding, and potential product-based development and regulatory milestone payments. Liquidia has also retained the ability to independently develop an inhaled treatment for a particular disease field.
09:59 EDTPFEActive equity options trading on open
Subscribe for More Information
08:37 EDTPFEPfizer lowers FY15 reported EPS view to $1.29-$1.38 from $1.38-$1.47
Subscribe for More Information
08:32 EDTPFEPfizer raises FY15 adjusted EPS view to $2.04-$2.10 from $2.01-$2.07
Subscribe for More Information
September 29, 2015
16:08 EDTPFELpath names Gary Atkinson as interim CEO
Lpath (LPTN) announced that Gary Atkinson has been appointed interim CEO of Lpath, effective immediately. Atkinson will continue to serve as Lpath's CFO. Atkinson joined Lpath as CFO in 2005, and has more than 20 years of experience with life science companies. Prior to Lpath, he served as the CFO for Quorex Pharmaceuticals, which was acquired by Pfizer (PFE).
16:00 EDTPFEOptions Update; September 29, 2015
Subscribe for More Information
14:20 EDTPFEPfizer's Wyeth to perform about $194M of cleanup work at Superfund site in NJ
Subscribe for More Information
September 28, 2015
15:01 EDTPFEPfizer volatility at high end of one-year range
Subscribe for More Information
07:52 EDTPFE, GSKIIR Holdings to hold a conference
Subscribe for More Information
07:27 EDTPFEFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
September 27, 2015
16:58 EDTGSKGlaxoSmithKline, Theravance report Phase 3 data on Anoro Ellipta for COPD
Subscribe for More Information
September 25, 2015
16:00 EDTPFEOptions Update; September 25, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 25.09. Option volume leaders: AAPL NFLX BAC FB AU NKE PFE INTC AMZN TSLA
09:34 EDTPFEActive equity options trading on open
Active equity options trading on open: AAPL BAC FB NKE NFLX PFE AU TSLA
07:22 EDTPFEEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
07:03 EDTPFEMerck KGaA, Pfizer announce FDA orphan drug designation for avelumab
Subscribe for More Information
05:08 EDTPFEStocks with implied volatility movement; PFE HLF
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use